The estimated Net Worth of Frank Witney is at least $21 Milion dollars as of 9 May 2024. Frank Witney owns over 20,000 units of Revvity stock worth over $20,759,002 and over the last 10 years he sold PKI stock worth over $0. In addition, he makes $264,976 as Independent Director at Revvity.
Sign up
Frank Witney PKI stock SEC Form 4 insiders trading
Frank has made over 4 trades of the Revvity stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of PKI stock worth $37,800 on 9 May 2024.
The largest trade he's ever made was buying 24,096 units of Revvity stock on 29 January 2020 worth over $99,998. On average, Frank trades about 2,855 units every 65 days since 2014. As of 9 May 2024 he still owns at least 180,059 units of Revvity stock.
You can see the complete history of Frank Witney stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Frank Witney biography
Dr. Franklin R. (Frank) Witney , Ph.D., is Independent Director of the Company. He most recently served as President and Chief Executive Officer of Affymetrix, Inc., which specialized in microarray technology and cellular analysis, from 2011 through March 2016 when it was acquired by Thermo Fisher Scientific Inc. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market leading ion and high performance liquid chromatography company from 2009 to 2011. Prior to that, Dr. Witney served as Executive Vice President and Chief Commercial Officer of Affymetrix from 2008 to 2009, following its acquisition of Panomics, Inc., a quantitative biology company, which Dr. Witney had led as President and Chief Executive Officer from 2002 to 2008. He previously held the role of President of PerkinElmer’s Drug Discovery Tools division following PerkinElmer’s acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio-Rad Laboratories beginning in 1983, leading that company’s efforts to enter the proteomic and bioassay technologies market. Dr. Witney was a post-doctoral fellow at the National Institutes of Health and holds a PhD in molecular and cell biology and a Master of Science degree in microbiology from Indiana University, as well as a Bachelor of Science degree in microbiology from the University of Illinois. Dr. Witney is a member of the board of directors of publicly traded Cerus Corporation, and a member of the board of RareCyte, Inc., Nexcelom Bioscience LLC, Emulate, Inc., Canopy Biosciences, LLC and GenapSys, Inc., all of which are privately held, and is an Operating Partner at Ampersand Capital Partners.
What is the salary of Frank Witney?
As the Independent Director of Revvity, the total compensation of Frank Witney at Revvity is $264,976. There are 11 executives at Revvity getting paid more, with Dr. Prahlad R. Singh Ph.D. having the highest compensation of $4,862,149.
How old is Frank Witney?
Frank Witney is 66, he's been the Independent Director of Revvity since 2016. There are 1 older and 20 younger executives at Revvity. The oldest executive at Revvity Inc. is Peter Barrett, 67, who is the Independent Director.
What's Frank Witney's mailing address?
Frank's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE, CONCORD, CA, 94520.
Insiders trading at Revvity
Over the last 26 years, insiders at Revvity have traded over $204,298,889 worth of Revvity stock and bought 55,200 units worth $1,110,570 . The most active insiders traders include Alexis P Michas, Gregory L Summe a Robert F Friel. On average, Revvity executives and independent directors trade stock every 25 days with the average trade being worth of $6,184,617. The most recent stock trade was executed by Andrew Okun on 13 April 2023, trading 2,435 units of PKI stock currently worth $332,402.
What does Revvity do?
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, the company delivers unique solutions to serve the diagnostics, life sciences, food, and applied markets. IT strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.
What does Revvity's logo look like?
Complete history of Frank Witney stock trades at Cerus, Revvity a Telesis Bio Inc
Revvity executives and stock owners
Revvity executives and other stock owners filed with the SEC include:
-
Dr. Prahlad R. Singh Ph.D.,
CEO, Pres & Director -
Prahlad Singh,
President, Chief Executive Officer, Director -
Joel Goldberg,
Senior Vice President - Administration, General Counsel, Secretary -
James M. Mock,
Sr. VP & CFO -
Joel S. Goldberg,
Sr. VP of Admin., Gen. Counsel & Sec. -
James Mock,
Chief Financial Officer, Senior Vice President -
Deborah Butters,
Chief Human Resource Officer, Senior Vice President -
Tajinder Vohra,
Sr. VP of Global Operations -
Alexandros Michas,
Independent Non-Executive Chairman of the Board -
Samuel Chapin,
Independent Director -
Peter Barrett,
Independent Director -
Pascale Witz,
Independent Director -
Frank Witney,
Independent Director -
Sylvie Gregoire,
Independent Director -
Michel Vounatsos,
Independent Director -
Andrew Okun,
Chief Accounting Officer, Vice President -
Tajinder Vohra,
Senior Vice President, Global Operations -
Daniel Tereau,
Senior Vice President, Strategy and Business Development -
Masoud Toloue,
Sr. VP of Diagnostics -
Miriame Victor,
Sr. VP & Chief Commercial Officer -
Robert Francis Friel,
Advisor -
Stephen Barr Willoughby,
VP of Investor Relations -
Andrew Okun,
VP, Chief Accounting Officer & Treasurer -
Michelle Mc Murry Heath,
Director -
Nicholas A Lopardo,
Director -
James Corbett,
See Remarks -
Alexis P Michas,
Director -
Vicki L Sato,
Director -
Kenton J Sicchitano,
Director -
Robert F Friel,
Chief Financial Officer -
Patrick J Sullivan,
Director -
Frank Anders Wilson,
SVP, CFO & CAO -
John A Roush,
Vice President -
Michael Louis Battles,
VP & Chief Accounting Officer -
Jeffrey D Capello,
Chief Accounting Officer -
Gregory L Summe,
Chairman & CEO -
Katherine A O Hara,
SVP & General Counsel -
Richard F Walsh,
Senior Vice President -
Tamara J Erickson,
Director -
Robert A Barrett,
Sr. Vice President -
Terrance L Carlson,
Sr. VP & General Counsel -
Peter B Coggins,
Sr. Vice President -
John Patrick Murphy,
Sr. Vice President -
John R Letcher,
Senior Vice President, HR -
Jonathan P. Di Vincenzo,
See Remarks -
James C Mullen,
Director -
Maurice H. Tenney,
See Remarks -
Daniel R Marshak,
SVP & CSO -
E Kevin Hrusovsky,
See Remarks -
G Robert Tod,
Director -
Gabriel Schmergel,
Director -
Miriame Victor,
Please See Remarks -
Maxwell Krakowiak,
Please See Remarks